Checkpoint Therapeutics Inc is a biotechnology business based in the US. Checkpoint Therapeutics shares (CKPT) are listed on the NASDAQ and all prices are listed in US Dollars. Checkpoint Therapeutics employs 10 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $2.45 |
|---|---|
| 52-week range | $2.22 - $5.38 |
| 50-day moving average | $3.21 |
| 200-day moving average | $3.01 |
| Wall St. target price | $15.80 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.52 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.45 from 2022-01-18
| 1 week (2022-01-09) | N/A |
|---|---|
| 1 month (2021-12-17) | -16.67% |
| 3 months (2021-10-18) | -22.47% |
| 6 months (2021-07-20) | -12.19% |
| 1 year (2021-01-20) | -33.60% |
|---|---|
| 2 years (2020-01-17) | 35.36% |
| 3 years (2019-01-18) | 3.6 |
| 5 years (2017-01-20) | 11 |
| Revenue TTM | $279,000 |
|---|---|
| Gross profit TTM | $-15,283,000 |
| Return on assets TTM | -44.87% |
| Return on equity TTM | -88.22% |
| Profit margin | 0% |
| Book value | $0.58 |
| Market capitalisation | $218.6 million |
TTM: trailing 12 months
We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $2.22 up to $5.376. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.6031. This would suggest that Checkpoint Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Checkpoint Therapeutics, Inc. , a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7. 1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.